Overall, we found that neither ovarian tumor densities of ov-CD68+ or CD163+ ov-TAMs nor the ratio of ovarian CD68+/CD163+ ov-TAMs was significantly associated with patient OS or PFS (Table 2, Table 3, Figure S3). This evidence concerns the gene CD163 and ovarian neoplasm.